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tions increased as the frequency and severity of exacerbations
increased. CONCLUSION: This was the ﬁrst study that gener-
ated COPD-speciﬁc utilities for health proﬁles that included the
health status during exacerbations. Their compatibility with
TTO values of the EQ-5D requires discussion.
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OBJECTIVES: COPD is a cause of high morbidity and mortal-
ity in the population, associated with high individual and social
burden. Projections for 2020 indicate an increase in COPD mor-
tality from the 6th to the 3rd position. Recent discussions 
conducted in the ﬁeld of COPD suggest that achievement of sys-
tematic treatment is accomplished through timely diagnosis of
the disease. Although there is no clear consensus on the treat-
ment patterns for COPD, there is a need to gain a better insight
into approaches of COPD management that better ﬁt the needs
of patients. The aim of this study was to obtain information on
patient perception of the disease, to investigate ways of control
and management of COPD, to examine patient adaptation to
treatment, as well as to assess how COPD affects patients’ life.
METHODS: This study was conducted in 79 primary care physi-
cian (GP/specialists) practices and involved one visit to complete
an extensive questionnaire. The questionnaire contained demo-
graphic data of patients, their symptoms, their pharmaceutical
treatment and their concerns for COPD. RESULTS: In total,
interviewer administered questionnaires were answered by 474
patients (62.7% male, 37.3% female). From those, 53% were
smokers, 97% had symptoms (bronchitis 16.5%, chronic cough
20.3%, asthma 18.4%, chest tightness 11.5%) whereas 80% of
patients received regular pharmaceutical treatment. Satisfaction
from their medication was expressed by 76% of patients,
although 83% express concerns for disease deterioration. 30%
of patients stated that COPD poses an obstacle for their daily
life. CONCLUSIONS: COPD is an impediment for the normal
life of patients. Symptoms are evident, even though patients
receive treatment. Strong concerns from patients themselves are
expressed regarding possible deterioration of their condition.
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OBJECTIVES: Biological therapies are considered effective for
treating chronic plaque psoriasis. We compared two methods of
indirect statistical analyses to assess the relative efﬁcacies of these
treatments. METHODS: A literature search was undertaken to
identify all relevant randomized controlled trials (RCTs) evalu-
ating alefacept, efalizumab, etanercept and inﬂiximab in patients
with psoriasis. Relative risks (RRs) with 95% conﬁdence inter-
vals were calculated for primary outcome measures (i.e., Psoria-
sis Area Severity Index (PASI)75 response rates at week 10/12)
using the Mantel-Haenszel method. Heterogeneity was estimated
across trials, and the null hypothesis (study effects were homo-
geneous) was tested. Treatments were also compared in an evi-
dence synthesis with endpoints jointly modeled using an ordered
probit model. This mixed treatment comparison was imple-
mented as a Bayesian hierarchical model. RESULTS: A compar-
ison of predicted probabilities and relative risks with the
Mantel-Haenszel calculated results indicated a good ﬁt for the
Bayesian model. In terms of RR compared to placebo, inﬂiximab
is the most effective for the PASI 75 response (Mantel-Haenszel
Relative Risk (MHRR) 18.23, 95%CI 8.45 to 39.34; Bayesian
Relative Risk (BRR) 20.53, Bayesian Conﬁdence Interval (BCI)
16.75 to 25.05). The next most effective was etanercept 50 mg
(MHRR 11.92, 95%CI 8.17 to 17.39; BRR 12.39, BCI 10.10 to
15.12) followed by etanercept 25 mg (MHRR 10.68, 95%CI
6.15 to 18.57; BRR 8.87, BCI 7.02 to 11.10) then efalizumab
(MHRR 7.47, 95%CI 5.20 to 10.73; BRR 7.27, BCI 5.88 to
8.92) then alefacept (MHRR 3.37, 95%CI 2.18 to 5.23; BRR
4.49, BCI 3.44 to 5.79). The ordering of effectiveness seen in
PASI 75 response was reﬂected in results for other outcomes (i.e.,
PASI 50, 90 and response rates). CONCLUSIONS: Two statis-
tical methods for meta-analysis give comparable results and
demonstrate that inﬂiximab is signiﬁcantly more effective at
week 10/12 than other currently available biological therapies
for chronic plaque psoriasis.
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OBJECTIVE: Biologics have the most favorable clinical proﬁle
required for the management of moderate to severe psoriasis.
However, costs and patients’ adherence related to biologics are
important factors to consider while making informed decisions
regarding the biologics therapy in psoriasis management. This
study examined predictors of biologics related adherence, total
health care costs, and service utilization among psoriasis patients
enrolled in Medicaid program. METHODS: This was a longitu-
dinal cohort study of psoriasis patients (<65 years old) enrolled
in North Carolina Medicaid who were prescribed one of the bio-
logics (alefacept, efalizumab, and etanercept) approved by the
US Food and Drug Administration during the study period.
Patients’ medication adherence, total health care costs, and
service utilization (hospitalizations, inpatient and outpatients
visits) patterns in pre- and post-biologics period were examined.
RESULTS: Adherence to biologics was signiﬁcantly higher as
compared with the other psoriasis medications (0.66 vs. 0.39; P
< 0.001). Prescription drug costs was signiﬁcantly higher in 
the post-biologics period ($3796.77 vs. $11706.32; p < 0.001).
However, total health care costs in the post-biologic period did
not differ signiﬁcantly from pre-biologic period ($14,662.22 vs.
$16,156.1; p > 0.05). Patients’ adherence and health care costs
did not differ signiﬁcantly across biologics. After controlling for
other variables, patients had signiﬁcantly lower number of hos-
pitalizations in the post-biologic period (p < 0.001). Adherence
related to psoriasis medications (biologics and other psoriasis
medications) remained the strongest predictors of number of ED
visits in the study cohort (both p < 0.001) CONCLUSIONS:
Although costs associated with biologic prescriptions were
higher, total health care costs did not differ signiﬁcantly in the
post-biologics period. Biologics had a better adherence rate as
compared to other psoriasis medications. Increased medication
adherence was associated with a lower number of ED visits.
